Results 141 to 150 of about 4,490 (182)
Taletrectinib as an emerging therapy for ROS1-positive non-small cell lung cancer: findings from TRUST phase 2 trials. [PDF]
Ann Med Surg (Lond)Khalid H +5 more
europepmc +1 more source
Entrectinib: First Global Approval
Drugs, 2019 Entrectinib (Rozlytrek®) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment
Zaina T, Al-Salama, Susan J, Keam
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Personalized Medicine, 2020 Targeting oncogenic fusion-genes in pediatric high-grade gliomas (pHGG) with entrectinib has emerged as a highly promising therapeutic approach.
Felix Sahm +2 more
exaly +3 more sources
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Expert Opinion on Investigational Drugs, 2015 Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation.
Rossana Ruiz +2 more
exaly +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met ...
openaire +1 more source
CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met ...
openaire +1 more source